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Introduction
Diabetes mellitus is associated with high-risk compli-
cations, essentially micro- and macrovascular compli-
cations (1). The neuropathies are among the most
common of the long-term complications of diabetes,
affecting up to 50% of patients (2). The most com-
mon type of diabetic neuropathy is a mixed (both
motor and sensory), symmetrical, distal and primar-
ily sensory polyneuropathy (3).
Electrodiagnostic testing plays a key role in the
characterization of neuropathies (4) and its use in
the diagnosis of diabetic polyneuropathy represents
an extension of the clinical examination and include
studies of sensory and motor nerve conduction, late
response recordings such as of the F wave, and nee-
dle electromyography. Electrodiagnostic ﬁndings
should conﬁrm the clinical ﬁndings and in some
cases allow the detection of subclinical abnormalities
(3).
Diabetic neuropathies cause morbidity with signiﬁ-
cant impact on the quality of life patients with diabe-
tes (5–7). The quality of life is one of the most
important indications, being very important for
health, and it is a measure of physical–social func-
tions and physical and spiritual wellbeing. Patients
with diabetes lead low-quality lives when compared
with healthy individuals. It was reported that the
most important factors being effective on the quality
of life in these patients are the complications pro-
gressing during the course of the illness was identi-
ﬁed (8). It is now widely accepted that the goals of
therapy in patients with chronic disease are not only
to improve survival, but also to improve quality of
life. Investigation of patient quality of life may pro-
vide useful information to set up standards for the
process of medical and nursing care (9). Advanced
practice nurses are in a unique position to imple-
ment strategies for the prevention of serious and
debilitating complications from diabetic neuropathy,
including foot assessment, education and specialist
referrals (10). Our study was conducted to evaluate
the effect of diabetic polyneuropathy, being one of
these complications, on the quality of life.
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SUMMARY
Objective: This study was performed to identify the relationship between the
quality of life and polyneuropathy which is one of the complications of diabetes.
Methods: Total 111 patients with diabetes mellitus were taken into the study as
type 1 and type 2. Patients were accepted having polyneuropathy according to
their electroneuromyography (ENMG) results. To evaluate the quality of life in the
patients Short Form 36 (SF-36) and World Health Organization Quality of Life
Questionnaire abbreviated version (WHOQOL-BREF) were used. Results: Clinical
polyneuropathy was found in 46% of the patients, while polineuropathy was found
in 63% of the patients with evaluation ENMG. The patients with polyneuropathy
had poor quality of life according to SF-36 and WHOQOL-BREF (p < 0.001). The
mean quality of life scores of patients who had sensoriomotor and mix polyneurop-
athy, were lower than sensory type and axonal polyneuropathy. Conclusion: Dia-
betic polyneuropathy inﬂuences the quality of life in a negative way. The quality of
life scores of patients who had polyneuropathy continuing with mixed pathogenesis
and sensoriomotor type, become worse for this reason, even if the patients do not
have any clinical polyneuropathy, this being evaluated with ENMG.
What’s known
It is now widely accepted that the goals of therapy
in patients with chronic disease are not only to
improve survival, but also to improve quality of life.
Diabetic neuropathy negatively affects the quality of
life of the patients.
What’s new
Evaluation of ENMG is important for the early
diagnosis of neuropathy. Taking necessary
precautions according to the results of ENMG will
be useful for improving the quality of life.
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This investigation was carried out between 2004 and
2005 on diabetic patient who applied to the depart-
ment of endocrinology.
Study sample
At the ﬁrst stage of the investigation, consent was
provided by patients who will participate in the
study. Patients who had microalbuminuria were
included in the study (albumin excretion rate of 20–
200 lg⁄min (30–300 mg⁄day). Microalbuminuria is
an important clinical ﬁnding because it is not only
associated with an increased risk of progression to
overt proteinuria (macroalbuminuria) and renal fail-
ure, but also cardiovascular events. In patients who
progress to overt nephropathy, microalbuminuria
usually precedes macroalbuminuria by an interval of
5–10 years (11). The presence of diabetic polyneur-
opathy in the patients was evaluated both clinically
and with electroneuromyography (ENMG). Patients
were accepted having polyneuropathy according to
their ENMG results.
The form of questionnaire
The questionnaire form containing information
related to data about sociodemographical features
were formed by the researchers for data collection
presenting the existence of microalbuminuria, and
the level of HbA1c. A Short Form 36 (SF-36) and
World Health Organization Quality of Life Question-
naire abbreviated version (WHOQOL-BREF) consist-
ing of 26 questions were used.
The Medical Outcomes SF-36 was used to evaluate
quality of life. The SF-36, which was developed by
Ware and Sherbourne (12), assesses eight health con-
cepts: physical functioning (PF), role limitations
because of physical problems (RP), social functioning
(SF), role limitations due to emotional problems
(RE), mental health (MH), vitality (VT), bodily pain
(BP) and general health (GH) perception. In this
study, the quality of life was evaluated as three mean
dimensions like GH perception, functional status
(PF + RP + SF + RE), wellness (MH + VT + BP)
and global score. Thirty-six substances take place in
the measure while two substances of the questions
were being answered in the form of yes⁄no, and the
others are in the form of ‘Likert’ (with three or with
six). All raw scale scores were linearly converted from
zero (worst possible health status or quality of life)
to 100 (best possible health status or quality of life).
The score of the subgroups as well as the ﬁnal global
score of the SF-36 changes between 0 and 100,
respectively and higher score mean good quality of
life. These measures provide a speed evaluation and
it was ﬁlled in 5–10 min (12–14). Different language
versions of the SF-36 are available, including Turk-
ish. Pinar (13) performed SF-36’s validation in Turk-
ish patients (1995). In her study the test–retest
correlation was 0.94 and Cronbach alpha value was
0.92.
As there were no questions about sexual function
in SF-36, it was used together with WHOQOL-BREF,
which also measures quality of life (15,16). WHO-
QOL-BREF which was composed of four domain
factors (physical, psychological, social relations and
the environment), was used to assess quality of life.
Each of four domains had a possible score ranged
between zero (poor quality of life) and 20 (excellent
quality of life) and higher score mean good quality
of life. WHOQOL-BREF was developed by WHO as
a measure for the life of quality. Twenty-six ques-
tions being in the type of Likert take a place in the
measure (17). The study of validity and reliability
was performed for the Turkish population in 1999
by Fidaner et al. (18). The values of Cronbach alpha
which is calculated in the study of reliability range
between 0.53 and 0.83.
Evaluation of diabetic polyneuropathy
Clinical evaluation
In the neurological evaluation performed by neurolo-
gist, with hypoesthesia of gloves-socks, hyporeﬂex or
areﬂex of biceps, pathella or achilles and motor loss
at least in two extremities were accepted as having
clinically polyneuropathy.
Electroneuromyographical evaluation
Study of ENMG was performed by the Keypoint
DANTEC device (Skovlunde, Denmark). Stimulation
duration was 0.2 ms for motor, and 0.1 ms for sen-
sory stimuli. All stimulations were performed supra-
maximally. Bipolar stimulus electrodes were used for
all stimuli. Sensory examinations were all performed
using the antiradical method. The band of frequen-
cies was 20 Hz to 10 kHz in the sensory, motor and
F-wave examinations. Nerve conduction velocity
(NCV) under limit for the upper extremity was
accepted as 50 m⁄s for motor conduction velocity
(MCV) and 43 m⁄s for sensory conduction velocity
(SCV). Also, NCV under limit for the lower extrem-
ity was 42 m⁄s MCV and SCV. Under limit the
amplitude of motor unit potential (MUP) was taken
as 6 mV for the median and ulnar nerve, 3 mV for
peroneal nerve and 4 mV for tibial nerve. The ampli-
tude of the sensory nerve action potential was
accepted as 10 lV for the median and ulnar nerves
1020 Subtypes of diabetic polyneuropathy and its impact on quality of life
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, July 2008, 62, 7, 1019–1025and as 6 lV for the sural and peroneal superﬁcial
nerves. The tibial F-wave upper limit was accepted as
55 ms. Polyneuropathy was divided into three groups
as motor, sensory and sensoriomotor electro physio-
logically according to involvement of the sensory and
motor nerves. The median nerve motor distal latency
over 4.4 ms and the SCV lower than 42 m⁄s and
fourth ﬁnger median-ulnar sensory peak difference
> 0.5 m⁄s were accepted as electrophysiological car-
pal tunnel syndrome (CTS). In respect of the patho-
genesis of polyneuropathy the phenomena was
divided into three groups according to the following
criteria; these were demyelization polyneuropathy,
axonal polyneuropathy or mixed polyneuropathy.
Prolongation of motor distal latency more than 30%
of normal, decrease of conduction velocity more
than 25% of normal, prolongation of F wave more
than 55 ms conduction block (so that the rate of
proximal⁄distal amplitude MUP is under 50%) or
temporal dispersion (so that the rate of proxi-
mal⁄distal MUP duration is more than 1.15) were
evaluated as demyelization polyneuropathy. Decrease
of motor and sensorial amplitude more than 40% of
normal value and⁄or presence denervation potentials
(ﬁbrillation potential and positive sharp waves) in
the needle ENMG were evaluated as axonal poly-
neuropathy (19).
Statistical evaluation
The statistical package for social science (spss; SPSS,
Chicago, IL, USA) for windows was used for statisti-
cal analysis. For comparison between distribution of
sociodemographic features and incidence of poly-
neuropathy chi-squared test, quality of life and inci-
dence of polyneuropathy Student t-test, quality of
life and type of polyneuropathy, classiﬁcation of
polyneuropathy and presence of microalbuminuria
Mann–Whitney U-tests were used. Linear regression
analysis was used to investigate the most signiﬁcant
factor for poor quality of life. The parametric test
was selected as the tests indicating normal distribu-
tion, and non-parametric tests were selected as those
which did not indicate normal distribution. The level
of signiﬁcance was set at p < 0.05.
Results
A total of 111 patients (66 females and 45 males)
were included in the study; 21 of them were with
type 1 diabetes and 90 with type 2 diabetes. The
mean age of patients was 53.1 ± 12.3 years. The
sociodemographical features of diabetic patients are
given in the Table 1. Polyneuropathy was found in
the 63% of the patients, but was not found in 37%
of the patients. In the group with polyneuropathy,
clinical polyneuropathy and duration of diabetes
were found to be more signiﬁcant (p < 0.05). No
signiﬁcant difference was found between age, gender,
diabetes types, HbA1c levels and microalbuminuria
with polyneuropathy (p > 0.05). But the frequency
presence of polyneuropathy was found to be higher
in female patients. Sensoriomotor type of polyneur-
opathy was found in 82% of the patients, while 19%
of them had sensory type of polyneuropathy. How-
ever, there were no patients with motor type poly-
neuropathy. In respect of the pathogenesis of
polyneuropathy, 73% of patients had axonal poly-
neuropathy, while 27% had mixed type polyneuropa-
thy. There were no patients with demyelination
polyneuropathy.
The relationship between the mean effect of the
quality of life of polyneuropathy are given in the
Table 2. Mean effects of the quality of life of patients
with the polyneuropathy was signiﬁcantly lower than
that of patients without polyneuropathy (p < 0.001).
The subparameters of SF-36 and WHOQOL-BREF
quality of life measures such as functional, wellbeing,
general, global, physical, psychologic, social and envi-
ronmental were found to be low in the polyneuropa-
thy group (p < 0.001).
Table 1 Distribution of sociodemographic features
according to the incidence of polyneuropathy
Features
Polyneuropathy
Positive
(%)
Negative
(%)
Total
(%) p
Age (years)
18–35 5 (9.8) 5 (8.3) 10 (9) 0.897
36–53 20 (39.2) 26 (43.3) 46 (41.5)
54 and › 26 (51) 29 (48.4) 55 (49.5)
Gender
Female 48 (69) 18 (44) 66 (60) 0.199
Male 22 (31) 23 (56) 45 (40)
Duration of diabetes
10 years ﬂ 16 (31) 38 (63) 54 (49) 0.001
10 years › 35 (69) 22 (37) 57 (51)
Type of diabetes
Type 1 10 (14) 11 (27) 21 (19) 0.085
Type 2 60 (86) 30 (73) 90 (81)
Clinical polyneuropathy
Positive 51 (73) – 51 (46) 0.001
Negative 19 (27) 41 (100) 60 (54)
HbA1c
< 7 30 (43) 12 (30) 42 (38) 0.110
‡ 7 40 (57) 29 (70) 69 (62)
Microalbuminuria
Positive 14 (20) 4 (10) 18 (16) 0.125
Negative 56 (80) 37 (90) 93 (84)
Total (%) 70 (63) 41 (37) 111 (100)
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and sensoriomotor polyneuropathy groups are com-
pared in Table 3. No signiﬁcant difference was found
between them (p > 0.05).
Comparison of the axonal and mix-type polyneur-
opathy groups is also made in Table 4, and no signif-
icant difference was found between the two groups
(p > 0.05). No signiﬁcance was found in the quality
of life parameter, functional subunits of SF-36 and in
the environmental subparameters of WHOQOL-
BREF, in respect of the presence of microalbuminuria
(p > 0.05). Wellbeing, general and global parameters
of SF-36, and the physical, psychologic and social
parameters of WHOQOL-BREF were found to be sig-
niﬁcant (p < 0.05). To ﬁnd out the basic factors
which reduce the quality of life, triple cross
tables were constructed because of the low quality of
life of patients with polyneuropathy and microalbu-
minuria. Statistical analysis demonstrated that the
most basic factor affecting the quality of life of
patients with microalbuminuria was polyneuropathy
(Table 5).
Table 2 Comparison of the SF-36 and WHOQOL-
BREF quality of life measurements according to
incidence of polyneuropathy
The mean
quality
of life
Polyneuropathy
Present
(n = 70)
Absent
(n = 41) p
SF-36
Functional 34.54 ± 2.85 62.76 ± 4.62 0.001
Wellbeing 32.92 ± 2.21 56.38 ± 3.16 0.001
General 34.41 ± 2.20 50.87 ± 3.13 0.001
Global 33.72 ± 1.88 57.34 ± 2.93 0.001
WHOQOL-BREF
Physical 9.63 ± 0.37 13.95 ± 0.44 0.001
Psychological 12.02 ± 0.36 14.04 ± 0.42 0.001
Social 11.39 ± 0.34 14.30 ± 0.51 0.001
Environmental 11.83 ± 0.31 14.06 ± 0.39 0.001
SF-36, Short Form 36; WHOQOL-BREF, World Health Organiza-
tion Quality of Life Questionnaire abbreviated version.
Table 3 Comparison of the patients’ mean quality of
life according to the type of polyneuropathy
The mean
quality
of life
Polyneuropathy type
Sensoriomotor
(n = 57)
Sensorial
(n = 13) p
SF-36
Functional 33.3 ± 3.0 40.5 ± 7.7 0.502
Wellbeing 32.4 ± 2.3 39.8 ± 5.6 0.261
General 34.3 ± 2.6 38.9 ± 4.3 0.326
Global 33.3 ± 2.1 38.3 ± 4.0 0.287
WHOQOL-BREF
Physical 9.9 ± 0.4 9.0 ± 0.8 0.486
Psychological 11.7 ± 0.3 13.1 ± 0.7 0.063
Social 11.4 ± 0.3 11.3 ± 0.7 0.915
Environmental 11.6 ± 0.3 12.1 ± 0.5 0.544
SF-36, Short Form 36; WHOQOL-BREF, World Health Organiza-
tion Quality of Life Questionnaire abbreviated version.
Table 4 Comparison of the patients’ mean quality of
life according to the classiﬁcation of polyneuropathy
The mean
quality
of life
Classiﬁcation of polyneuropathy
Axonal
(n = 51)
Mix
(n = 13) p
SF-36
Functional 36.1 ± 3.4 30.5 ± 4.9 0.402
Wellbeing 35.2 ± 2.6 30.0 ± 4.0 0.345
General 34.2 ± 2.4 32.8 ± 5.6 0.701
Global 34.8 ± 2.2 32.8 ± 4.0 0.602
WHOQOL-BREF
Physical 9.7 ± 0.4 9.5 ± 0.7 0.995
Psychological 12.3 ± 0.3 11.1 ± 0.6 0.118
Social 11.7 ± 0.4 10.6 ± 0.5 0.170
Environmental 12.0 ± 0.3 10.8 ± 0.5 0.065
SF-36, Short Form 36; WHOQOL-BREF, World Health Organiza-
tion Quality of Life Questionnaire abbreviated version.
Table 5 Comparison of the quality of life
measurements of patients according to the presence of
microalbuminuria
The mean
quality
of life
Microalbuminuria
Present
(n = 18)
Absent
(n = 93) p
SF-36
Functional 38.1 ± 7.74 46.2 ± 2.9 0.133
Wellbeing 30.0 ± 5.0 44.7 ± 2.3 0.014
General 32.3 ± 5.8 42.0 ± 2.0 0.031
Global 33.5 ± 5.04 44.1 ± 2.0 0.035
WHOQOL-BREF
Physical 8.6 ± 8.8 11.7 ± 0.3 0.001
Psychological 11.3 ± 0.8 13.1 ± 0.3 0.027
Social 10.0 ± 0.8 12.9 ± 0.3 0.002
Environmental 11.7 ± 0.6 12.8 ± 0.2 0.322
SF-36, Short Form 36; WHOQOL-BREF, World Health Organiza-
tion Quality of Life Questionnaire abbreviated version.
1022 Subtypes of diabetic polyneuropathy and its impact on quality of life
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, July 2008, 62, 7, 1019–1025According to the results of linear regression analy-
sis; the WHOQOL-BREF scores on each of the
domains and SF-36 global score were low in poly-
neuropathy (p < 0.05). SF-36 global score and physi-
cal parameter of WHOQOL-BREF were low on the
patients who had diabetes for more 10 years, social
and physical parameter of WHOQOL-BREF were
low in presence of microalbuminuria, SF-36 global
and psychologic domain score of WHOQOL-BREF
were low in female (p < 0.05) (Table 6).
Discussion
Diabetic neuropathy is one of the most frequently
encountered complications of diabetes mellitus (6,7).
Previous studies indicated that diabetic neuropathy
progressed in the diabetic patients ranging from 16%
to 50% (20–24). In our study, according to neuro-
logical evaluation performed by neurologist clinical
polyneuropathy was found in 46% of the patients,
while polineuropathy was found in 63% of the
patients with evaluation ENMG.
Some studies indicated that advanced age and the
long duration of diabetes increased the prevalence
of polyneuropathy (25–28); however, no relationship
between the diabetic polyneuropathy and gender
could be found (25,26). Daousi et al. (29) could not
ﬁnd any relationship between age, type of diabetes,
gender, duration of the illness and the frequency of
peripheral neuropathy with chronic pain. According
to the results of our study, no signiﬁcant relation-
ship was found between the frequency of polyneur-
opathy and gender and type of diabetes. However,
the frequency of presence of polyneuropathy was
found to be higher in female patients and patients
having diabetes for more than 10 years. The cause
of polyneuropathy frequently seen in female patients
can be explained by the fact that female patients
have longer duration of diabetes than their male
counterparts.
Table 6 Results of linear regression analysis*
Parameters
Unstandardized
coefﬁcients
Standardized
coefﬁcients
t p B SE b
SF-36
Global
Constant 16.52 8.25 – 2.003 0.048
Polyneuropathy  19.38 3.36 0.461 5.767 0.000
Duration of diabetes )4.96 1.89 )0.210 )2.627 0.010
Female gender 6.96 3.26 0.168 2.133 0.035
WHOQOL-BREF
Physical
Constant 10.51 1.52 – 6.89 0.000
Polyneuropathy 3.69 0.58 0.48 6.30 0.000
Microalbuminuria )2.36 0.74 )0.23 )3.19 0.002
Duration of diabetes )0.76 0.32 )0.17 )2.32 0.022
Psychological
Constant 9.44 0.87 – 10.84 0.000
Polyneuropathy 0.63 0.20 0.28 3.12 0.002
Female gender 1.33 0.56 0.21 2.35 0.020
Social
Constant 11.70 1.29 – 9.04 0.000
Polyneuropathy 2.66 0.58 0.38 4.59 0.000
Microalbuminuria )2.47 0.75 )0.27 )3.26 0.001
Environmental
Constant 9.60 0.74 – 12.86 0.000
Polyneuropathy 2.22 0.51 0.38 4.32 0.000
*Several factors (age, female gender, duration of diabetes, type of diabetes, clinical polyneuropathy, HbA1c, microalbuminuria, poly-
neuropathy, type of polyneuropathy and classiﬁcation of polyneuropathy) were tested for regression analysis. Only signiﬁcant parame-
ters are given.  Polyneuropathy: according to ENMG. SF-36, Short Form 36; WHOQOL-BREF, World Health Organization Quality of Life
Questionnaire abbreviated version.
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tive method deﬁning subclinical and clinical
neuropathy (30). In our study, although patients did
not have clinical polyneuropathy, the presence of
polyneuropathy in ENMG indicated the importance
of ENMG in the early diagnosis of polyneuropathy.
Sensoriomotor polyneuropathy was demonstrated
82% of the patients in our study, whereas 19% of
patients had the sensory polyneuropathy. Lloyd et al.
(31) demonstrated that 12% of the patients with the
type 2 diabetes had peripheral sensory neuropathy.
Kastenbaur et al. (23) detected sensoriomotor neu-
ropathy in 48% of diabetic patients with abnormal
ankle reﬂex. The primary problem in the diabetic
polyneuropathies was known to be mostly axonal
polyneuropathy (32). In our study, the percentage of
axonal polyneuropathy phenomena complies with
the literature.
Several studies have demonstrated that diabetes
negatively inﬂuenced the quality of life (33,34) and
that polyneuropathy progressing because of diabetes
worsens the quality of life (6,7,35). We found the
mean value quality of life patients with polyneuropa-
thy to be low in our study.
Axonal polyneuropathies has a negative inﬂuence
on the quality of life. In a study on 90 patients with
chronic axonal neuropathy conducted using the
Health Survey Questionnaire (RAND-36), Teunissen
et al. (36), identiﬁed a low quality of life. In our study,
when the quality of life was examined according to the
pathogenesis of polyneuropathy, it was demonstrated
that subparameters of SF-36 (functional, wellbeing,
general and global) and WHOQOL-BREF (physical,
psychological, social and environmental) mean quality
of life the patients with mixed polyneuropathy was
lower than the patients with axonal polyneuropathy.
This case can be explained by the presence of
mixed polyneuropathy together with axonal and
demyelination polyneuropathy.
Many studies indicate that a good glycaemic con-
trol positively affects the quality of life (8,37–41). On
the contrary, some studies could not ﬁnd any rela-
tionship between the quality of life and the level of
HbA1c (42,43). In our study, it was demonstrated
that the level of HbA1c did not affect the quality of
life of patients. However, it is difﬁcult to comment
on this result as deteriorated glycaemic control did
not negatively affect the quality of life. As a matter
of fact, one of the most important factors in the pro-
gression of diabetic neuropathy and nephropathy is
the bad glycaemic control (44,45). Therefore,
although the level of HbA1c seems to not affect the
quality of life in a negative way, because of its role in
the development of complications, it can be said it
has a direct negative effect on the quality of life.
Our results indicated that, diabetic polyneuropathy
as diagnosed on ENMG negatively affects the quality
of life of the patients. Polyneuropathy with mixed
and sensoriomotor type may especially deteriorate
the quality of life to a greater extent. This led to the
consideration that the level of polyneuropathy
affected the quality of life. Evaluation of ENMG is
important for the early diagnosis of neuropathy.
Especially the patients who had clinical neuropathy,
microalbuminuria, long duration of diabetes and
female gender; should be speciﬁcally targeted for
ENMG evaluation and for taking necessary precau-
tions such as strict glycaemic control and strategies
to reduce diabetes-related complications (long term)
will be useful for improving the quality of life.
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